Will the Inflation Reduction Act actually increase drug affordability? Well…it’s complicated. RyanCox, VP, Director, PRECISIONvalue Access Experience Team, outlines the ways it will cut costs—and some watchouts. Learn more in this 90-second video.
How do you compete against a negotiated drug? As the Inflation Reduction Act challenges current formulary dynamics, PRECISIONvalue expert Erin Lopata has a succinct answer: Prove your value. Learn more in this 90-second video.
Accelerated FDA approvals are under scrutiny and at the center of many debates. Explore the complexities, benefits, and risks of accelerated approvals with Ross Maclean, EVP at PRECISIONheor & Head of Medical Affairs at Precision Value & Health, in an insightful discussion alongside Dr. Jason A. Mouabbi, Breast Medical Oncologist at MD Anderson.
Higher premiums. Increased brand exclusions. Limited treatment populations. Payers may deploy an arsenal of defenses against rising drug costs—and manufacturers should adapt to support patient access. Dominic Galante, Chief Medical Officer PRECISIONvalue, shares thoughts on effective strategies in this short Access90 video.
The rules of engagement for patient and caregiver communities have changed. Once off limit to industry insiders, patient communities are now opening their doors to pharma. What does this mean for pharma companies and how do you shift your strategy? Jack DeManche, Director of Digital Strategy at PRECISIONeffect, chats with MM+M and other industry leaders about the catalysts driving the shift towards greater community engagement, insights into the evolving landscape of patient involvement, and nuanced approaches to fostering collaborations.
In Part 2, Maureen Hennessey, SVP, Director of Value Transformation, PRECISIONvalue with Elizabeth Oyekan, VP Pharmacy and Imaging Services, Stanford Health Care and Valerie Nguyen, dive deeper into Navigating Health Equity in 2024, focusing on the significance of accreditations in addressing health disparities and promoting health equity, highlighting programs for achieving accreditation and advocating for the integration of social determinants of health (SDOH) and health equity practices within pharmacy and health care.
An expert view from Ross Maclean, Head of Medical Affairs and Jon Bambalas, SVP, Business Development, Precision Value & Health, on how insights from patient-level health insurance benefits data can serve the pharmaceutical industry – namely, how coverage insights can inform the generation of evidence to demonstrate to payers and providers the value of a specific treatment.
Register for a free trial subscription and read the article HERE!
2024 will be the first full year in which health systems will be held accountable by The Joint Commission (TJC) for performance on their National Patient Safety Goal to improve health care equity. Marueen Hennessey, SVP, Director of Value Transformation, PRECISIONvalue with Elizabeth Oyekan, VP Pharmacy and Imaging Services, Stanford Health Care and Valerie Nguyen, Healthcare Administration Graduate Intern at Stanford Health Care share their unique perspectives in this AJMC article.
Patients already look beyond their prescription benefits for ways to pay. As cost-sharing rises and payer formulary controls and exclusions expand, patient demand for new solutions will grow. PRECISIONvalue Chief Medical Officer Dominic Galante discusses the future of access management in this Access90 video.
The COVID-19 pandemic laid bare disparities in access to quality healthcare and resources that have led to poor outcomes among racial and ethnic minorities, socioeconomically vulnerable individuals, and populations in rural areas. With a renewed and keener scrutiny of health equity issues, the distributional consequences of a new intervention across subgroups should come to the forefront of discussions about value in health.
Join Precision HEOR for a webinar about studying the health equity impacts of new interventions. We will outline the conceptual basis of how health interventions can affect health equity and consider distributional cost-effectiveness analysis with decision-analytic models as a practical approach to assess this quantitatively. We will discuss the evidence needs and typical gaps for new interventions and how to optimize the use of existing data. The discussion will conclude with a live Q&A.